News
ARWR
--
0.00%
--
After Yesterday's Rally of 1.68% Shares Could Potentially Pullback
Arrowhead Pharma (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $82.51 to a high of $84.37. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $82.87 on volume of 1.4 million shares. Often times...
Comtex SmarTrend(R) · 5d ago
Is Vaccine Stock Novavax Still a Buy?
StockNews.com · 5d ago
After Yesterday's Decline of 4.32%, Arrowhead Pharma Offers Investors Better Value
Arrowhead Pharma (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $71.52 to a high of $74.75. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $74.50 on volume of 1.4 million shares. Often times af...
Comtex SmarTrend(R) · 01/05 17:12
SmarTrend Watching for Potential Rebound in Shares of Arrowhead Pharma After 3.28% Loss
Arrowhead Pharma (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $75.25 to a high of $79.88. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $79.81 on volume of 1.4 million shares. Often times af...
Comtex SmarTrend(R) · 12/29/2020 16:58
The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 22)
Benzinga · 12/23/2020 13:29
Is ARWR A Good Stock To Buy Now According To Hedge Funds?
Insider Monkey · 12/20/2020 02:18
Arrowhead Pharma Set to Possibly Pullback After Yesterday's Rally of 2.58%
Arrowhead Pharma (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $79.20 to a high of $81.55. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $79.65 on volume of 1.4 million shares. Often times...
Comtex SmarTrend(R) · 12/18/2020 17:04
The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14)
Benzinga · 12/15/2020 12:52
Watch for Arrowhead Pharma to Potentially Pullback After Gaining 5.31% Yesterday
Arrowhead Pharma (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $74.97 to a high of $78.20. Yesterday, the shares gained 5.3%, which took the trading range above the 3-day high of $75.03 on volume of 1.4 million shares. Often times...
Comtex SmarTrend(R) · 12/14/2020 17:30
The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 10)
Benzinga · 12/11/2020 13:11
Look for Shares of Arrowhead Pharma to Potentially Pullback after Yesterday's 2.44% Rise
Arrowhead Pharma (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $65.78 to a high of $67.50. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $66.42 on volume of 1.4 million shares. Often times...
Comtex SmarTrend(R) · 12/08/2020 17:17
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that as an inducement to entering into employment with the
Benzinga · 12/07/2020 21:10
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 4, 2020, the Compensation Committee of the Board of Directors approved "inducement" grants to 27 new employees un...
BusinessWire · 12/07/2020 18:10
ARWR: Update on Cardiometabolic Candidates
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Cardiometabolic Programs Offer Enormous Potential In November 2020, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) hosted KOL events for its lead cardiometabolic programs, ARO-APOC3 and ARO-ANG3. The company had previously announced encouraging results for each of those programs (see our previous update here ) and
Zacks Small Cap Research · 12/07/2020 11:38
ARWR: Update on Cardiometabolic Candidates
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Cardiometabolic Programs Offer Enormous Potential In November 2020, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) hosted KOL events for its lead cardiometabolic programs, AR...
Zacks Small Cap Research · 12/07/2020 11:38
NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the appointment of Curt Bradshaw, Ph.D., as its new Chief Scientif...
GlobeNewswire · 12/02/2020 13:00
NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer
GlobeNewswire · 12/02/2020 13:00
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
Arrowhead will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference and 20th Gordon L. Snider Critical Issues Workshop
Business Wire · 11/30/2020 21:00
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
BusinessWire · 11/30/2020 18:00
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
Business Wire · 11/25/2020 12:30
Webull provides a variety of real-time ARWR stock news. You can receive the latest news about Arrowhead Pharms through multiple platforms. This information may help you make smarter investment decisions.
About ARWR
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
More